Patents by Inventor David D. Roberts

David D. Roberts has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8951527
    Abstract: Described herein is the discovery that cell and tissue survival can be dramatically increased following radiation exposure through inhibition of the interaction between TSP-1 and CD47. This effect is shown using antisense molecules, peptides, and antibodies, which can now be used as radioprotectant agents. These agents find application in minimizing, reducing and/or preventing tissue damage following intentional and accidental radiation exposure, as well as increasing the therapeutic efficacy of radiation therapies by protecting non-target tissue from incidental radiation damage and by increasing tumor ablation following radiation treatment.
    Type: Grant
    Filed: August 5, 2009
    Date of Patent: February 10, 2015
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Jeffrey S. Isenberg, David D. Roberts, Justin Maxhimer
  • Patent number: 8865672
    Abstract: Provided herein are methods for preventing, ameliorating, and/or reducing tissue ischemia and/or tissue damage due to ischemia, increasing blood vessel diameter, blood flow and tissue perfusion in the presence of vascular disease including peripheral vascular disease, atherosclerotic vascular disease, coronary artery disease, stroke and influencing other conditions, by suppressing CD47 and/or blocking TSP1 and/or CD47 activity or interaction. Influencing the interaction of CD47-TSP1 in blood vessels allows for control of blood vessel diameter and blood flow, and permits modification of blood pressure and cardiac function. Under conditions of decreased blood flow, for instance through injury or atherosclerosis, blocking TSP1-CD47 interaction allows blood vessels to dilate and increases blood flow, tissue perfusion and tissue survival.
    Type: Grant
    Filed: July 11, 2012
    Date of Patent: October 21, 2014
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Jeffrey S. Isenberg, David D. Roberts
  • Patent number: 8557788
    Abstract: Provided herein are compositions for preventing, ameliorating, and/or reducing tissue ischemia and/or tissue damage due to ischemia, increasing blood vessel diameter, blood flow and tissue perfusion in the presence of vascular disease including peripheral vascular disease, atherosclerotic vascular disease, coronary artery disease, stroke and influencing other conditions, by suppressing CD47 and/or blocking TSP1 and/or CD47 activity or interaction. Influencing the interaction of CD47-TSP1 in blood vessels allows for control of blood vessel diameter and blood flow, and permits modification of blood pressure and cardiac function. Under conditions of decreased blood flow, for instance through injury or atherosclerosis, blocking TSP1-CD47 interaction allows blood vessels to dilate and increases blood flow, tissue perfusion and tissue survival.
    Type: Grant
    Filed: July 11, 2012
    Date of Patent: October 15, 2013
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Jeffrey S. Isenberg, David D. Roberts
  • Patent number: 8344019
    Abstract: The present invention relates to compositions and methods for the production of biliverdin and methods of treatment and prevention. In particular, the invention concerns methods for producing biliverdin in yeast, especially Candida albicans, and other microorganisms.
    Type: Grant
    Filed: February 13, 2012
    Date of Patent: January 1, 2013
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Michael L Pendrak, David D Roberts
  • Publication number: 20120295957
    Abstract: Provided herein are compositions for preventing, ameliorating, and/or reducing tissue ischemia and/or tissue damage due to ischemia, increasing blood vessel diameter, blood flow and tissue perfusion in the presence of vascular disease including peripheral vascular disease, atherosclerotic vascular disease, coronary artery disease, stroke and influencing other conditions, by suppressing CD47 and/or blocking TSP1 and/or CD47 activity or interaction. Influencing the interaction of CD47-TSP1 in blood vessels allows for control of blood vessel diameter and blood flow, and permits modification of blood pressure and cardiac function. Under conditions of decreased blood flow, for instance through injury or atherosclerosis, blocking TSP1-CD47 interaction allows blood vessels to dilate and increases blood flow, tissue perfusion and tissue survival.
    Type: Application
    Filed: July 11, 2012
    Publication date: November 22, 2012
    Inventors: Jeffrey S. Isenberg, David D. Roberts, William A. Frazier
  • Publication number: 20120295956
    Abstract: Provided herein are methods for preventing, ameliorating, and/or reducing tissue ischemia and/or tissue damage due to ischemia, increasing blood vessel diameter, blood flow and tissue perfusion in the presence of vascular disease including peripheral vascular disease, atherosclerotic vascular disease, coronary artery disease, stroke and influencing other conditions, by suppressing CD47 and/or blocking TSP1 and/or CD47 activity or interaction. Influencing the interaction of CD47-TSP1 in blood vessels allows for control of blood vessel diameter and blood flow, and permits modification of blood pressure and cardiac function. Under conditions of decreased blood flow, for instance through injury or atherosclerosis, blocking TSP1-CD47 interaction allows blood vessels to dilate and increases blood flow, tissue perfusion and tissue survival.
    Type: Application
    Filed: July 11, 2012
    Publication date: November 22, 2012
    Inventors: Jeffrey S. Isenberg, David D. Roberts, William A. Frazier
  • Patent number: 8236313
    Abstract: Provided herein are compositions and methods for preventing, ameliorating, and/or reducing tissue ischemia and/or tissue damage due to ischemia, increasing blood vessel diameter, blood flow and tissue perfusion in the presence of vascular disease including peripheral vascular disease, atherosclerotic vascular disease, coronary artery disease, stroke and influencing other conditions, by suppressing CD47 and/or blocking TSP1 and/or CD47 activity or interaction. Influencing the interaction of CD47-TSP1 in blood vessels allows for control of blood vessel diameter and blood flow, and permits modification of blood pressure and cardiac function. Under conditions of decreased blood flow, for instance through injury or atherosclerosis, blocking TSP1-CD47 interaction allows blood vessels to dilate and increases blood flow, tissue perfusion and tissue survival. This in turn reduces or prevents tissue necrosis and death.
    Type: Grant
    Filed: October 5, 2007
    Date of Patent: August 7, 2012
    Assignees: The United States of America, as represented by the Secretary of the Department of Health and Human Services, Washington University
    Inventors: Jeffrey S. Isenberg, David D. Roberts, William A. Frazier
  • Publication number: 20120142751
    Abstract: The present invention relates to compositions and methods for the production of biliverdin and methods of treatment and prevention. In particular, the invention concerns methods for producing biliverdin in yeast, especially Candida albicans, and other microorganisms.
    Type: Application
    Filed: February 13, 2012
    Publication date: June 7, 2012
    Applicant: The United States of America, As Represented by The Secretary, Department of
    Inventors: MICHAEL L. PENDRAK, DAVID D. ROBERTS
  • Patent number: 8114406
    Abstract: The present invention relates to a peptide comprising the sequence R1—X1—X2—X3—X4—R2, wherein X1 is selected from the group consisting of N, Q, D and S; X2 is selected from the group consisting of V, I and L; X3 is selected from the group consisting of R and K; and X4 is selected from the group consisting of V, I, L and F; R1 is a hydrogen or a peptide of 1 to 6 amino acids, an acyl or an aryl group; and R2 is a peptide of 1 to 3 amino acids, a hydroxide or an amide. The invention also relates to partial or full retro-inverso peptides comprising the above sequences The invention also relates to peptide-substrate combination comprising a substrate suitable for cell growth and the peptide of the invention, and to a vascular graft and an artificial blood vessel comprising the peptide-substrate combination. The invention also relates to a pharmaceutical composition and a peptide conjugate comprising the peptide of the invention.
    Type: Grant
    Filed: June 28, 2010
    Date of Patent: February 14, 2012
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: David D. Roberts, Henry C. Krutzsch
  • Publication number: 20110135641
    Abstract: Described herein is the discovery that cell and tissue survival can be dramatically increased following radiation exposure through inhibition of the interaction between TSP-1 and CD47. This effect is shown using antisense molecules, peptides, and antibodies, which can now be used as radioprotectant agents. These agents find application in minimizing, reducing and/or preventing tissue damage following intentional and accidental radiation exposure, as well as increasing the therapeutic efficacy of radiation therapies by protecting non-target tissue from incidental radiation damage and by increasing tumor ablation following radiation treatment.
    Type: Application
    Filed: August 5, 2009
    Publication date: June 9, 2011
    Inventors: Jeffrey S. Isenberg, David D. Roberts, Justin Maxhimer
  • Publication number: 20110009311
    Abstract: The present invention relates to a peptide comprising the sequence R1—X1—X2—X3—X4—R2, wherein X1 is selected from the group consisting of N, Q, D and S; X2 is selected from the group consisting of V, I and L; X3 is selected from the group consisting of R and K; and X4 is selected from the group consisting of V, I, L and F; R1 is a hydrogen or a peptide of 1 to 6 amino acids, an acyl or an aryl group; and R2 is a peptide of 1 to 3 amino acids, a hydroxide or an amide. The invention also relates to partial or full retro-inverso peptides comprising the above sequences The invention also relates to peptide-substrate combination comprising a substrate suitable for cell growth and the peptide of the invention, and to a vascular graft and an artificial blood vessel comprising the peptide-substrate combination. The invention also relates to a pharmaceutical composition and a peptide conjugate comprising the peptide of the invention.
    Type: Application
    Filed: June 28, 2010
    Publication date: January 13, 2011
    Applicants: DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: DAVID D. ROBERTS, HENRY C. KRUTZSCH
  • Patent number: 7745144
    Abstract: The present invention relates to a peptide comprising the sequence R1—X1—X2—X3—X4—R2, wherein X1 is selected from the group consisting of N, Q, D and S; X2 is selected from the group consisting of V, I and L; X1 is selected from the group consisting of R and K; and X4 is selected from the group consisting of V, I, L and F; R1 is a hydrogen or a peptide of 1 to 6 amino acids, and acyl or an aryl group; and R2 is a peptide of 1 to 3 amino acids, a hydroxide or an amide. The invention also relates to partial or full retro-inverso peptides comprising the above sequences. The invention also relates to peptide-substrate combination comprising a substrate suitable for cell growth and the peptide of the invention, and to a vascular graft and an artificial blood vessel comprising the peptide-substrate combination. The invention also relates to a pharmaceutical composition and a peptide conjugate comprising the peptide of the invention.
    Type: Grant
    Filed: August 23, 2006
    Date of Patent: June 29, 2010
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: David D. Roberts, Henry C. Krutzsch
  • Publication number: 20100112626
    Abstract: Method of diagnosing cancer in a mammal comprising assaying a test sample from the mammal for an increased level of semenogelin, wherein the increased level of semenogelin in the test sample is diagnostic for the cancer; methods of prognosticating and assessing the effectiveness of treatment of a cancer in a mammal based on the level of semenogelin in a test sample; a composition comprising (a) an immune-response inducing effective amount of (i) semenogelin or polypeptide fragment thereof or (ii) antibody thereto or (b) a recombinant vector encoding and expressing an immune-response inducing effective amount of (i) or (ii); a method of inducing an immune response to a cancer in a mammal comprising administering to the mammal the foregoing composition.
    Type: Application
    Filed: October 30, 2009
    Publication date: May 6, 2010
    Applicant: The United States of America, as represented by the Secretary, Dept. of Health & Human Services
    Inventors: David D. Roberts, Henry C. Krutzsch, Christine Krutzsch
  • Publication number: 20100092467
    Abstract: Provided herein are compositions and methods for preventing, ameliorating, and/or reducing tissue ischemia and/or tissue damage due to ischemia, increasing blood vessel diameter, blood flow and tissue perfusion in the presence of vascular disease including peripheral vascular disease, atherosclerotic vascular disease, coronary artery disease, stroke and influencing other conditions, by suppressing CD47 and/or blocking TSP1 and/or CD47 activity or interaction. Influencing the interaction of CD47-TSP1 in blood vessels allows for control of blood vessel diameter and blood flow, and permits modification of blood pressure and cardiac function. Under conditions of decreased blood flow, for instance through injury or atherosclerosis, blocking TSP1-CD47 interaction allows blood vessels to dilate and increases blood flow, tissue perfusion and tissue survival. This in turn reduces or prevents tissue necrosis and death.
    Type: Application
    Filed: October 5, 2007
    Publication date: April 15, 2010
    Inventors: Jeffrey S. Isenberg, David D. Roberts, William A. Frazier
  • Patent number: 7618789
    Abstract: Method of diagnosing cancer in a male mammal comprising obtaining and assaying a test sample for an increased level of semenogelin; method of diagnosing cancer in a female mammal comprising obtaining and assaying a test sample for the presence of semenogelin; methods of prognosticating and assessing the effectiveness of treatment of a cancer in a mammal comprising measuring the level of semenogelin in a test sample; method of inducing an immune response to a cancer in a mammal comprising administering to the mammal a composition comprising (a) an immune-response inducing effective amount of (i) semenogelin or (ii) antibody thereto or (b) a recombinant vector encoding and expressing an immune-response inducing effective amount of (i) or (ii); and composition comprising a carrier and (a) an immune-response inducing effective amount of (i) a polypeptide of any of SEQ ID NOS:1-27 or (ii) antibody thereto or (b) a recombinant vector encoding and expressing an immune-response inducing effective amount of (i) or (ii
    Type: Grant
    Filed: April 3, 2002
    Date of Patent: November 17, 2009
    Assignee: The United States of America as represented by the Secretary of Department of Health and Human Services
    Inventors: David D. Roberts, Henry C. Krutzsch, Christine Krutzsch, legal representative
  • Publication number: 20090203762
    Abstract: The present invention relates to compositions and methods for the production of biliverdin. In particular, the invention concerns methods for producing biliverdin in yeast, especially Candida albicans, and other microorganisms.
    Type: Application
    Filed: February 2, 2009
    Publication date: August 13, 2009
    Inventors: MICHAEL L. PENDRAK, DAVID D. ROBERTS
  • Patent number: 7504243
    Abstract: The present invention relates to compositions and methods for the production of biliverdin. In particular, the invention concerns methods for producing biliverdin in yeast, especially Candida albicans, and other microorganisms.
    Type: Grant
    Filed: March 14, 2005
    Date of Patent: March 17, 2009
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Michael L. Pendrak, David D. Roberts
  • Publication number: 20080249026
    Abstract: The present invention relates to a peptide comprising the sequence R1-X1-X2-X3-X4-R2, wherein X1 is selected from the group consisting of N, Q, D and S; X2 is selected from the group consisting of V, I and L; X1 is selected from the group consisting of R and K; and X4 is selected from the group consisting of V, I, L and F; R1 is a hydrogen or a peptide of 1 to 6 amino acids, and acyl or an aryl group; and R2 is a peptide of 1 to 3 amino acids, a hydroxide or an amide. The invention also relates to partial or full retro-inverso peptides comprising the above sequences. The invention also relates to peptide-substrate combination comprising a substrate suitable for cell growth and the peptide of the invention, and to a vascular graft and an artificial blood vessel comprising the peptide-substrate combination. The invention also relates to a pharmaceutical composition and a peptide conjugate comprising the peptide of the invention.
    Type: Application
    Filed: August 23, 2006
    Publication date: October 9, 2008
    Applicant: National Institutes of Health
    Inventors: David D. Roberts, Henry C. Krutzsch
  • Patent number: 7332167
    Abstract: Three hemoglobin-response genes in the pathogenic yeast Candida albicans are disclosed. The expression of these genes is specifically induced when the organism is exposed to hemoglobin during disseminated infections. The invention relates to the nucleic acid and amino acid sequences of these hemoglobin-response genes. The invention also relates to diagnostic methods, kits and compositions which employ the nucleic acid and amino acid sequences of the invention.
    Type: Grant
    Filed: February 18, 2005
    Date of Patent: February 19, 2008
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: David D. Roberts, Sizhuang (Steve) Yan
  • Patent number: 7129052
    Abstract: The present invention relates to a peptide comprising the sequence R1-X1-X2-X3-X4-R2, wherein X1 is selected from the group consisting of N, Q, D and S; X2 is selected from the group consisting of V, I and L; X3 is selected from the group consisting of R and K; and X4 is selected from the group consisting of V, I, L and F; R1 is a hydrogen or a peptide of 1 to 6 amino acids, and acyl or an aryl group; and R2 is a peptide of 1 to 3 amino acids, a hydroxide or an amide. The invention also relates to partial or full retro-inverso peptides comprising the above sequences. The invention also relates to peptide-substrate combination comprising a substrate suitable for cell growth and the peptide of the invention, and to a vascular graft and an artificial blood vessel comprising the peptide-substrate combination. The invention also relates to a pharmaceutical composition and a peptide conjugate comprising the peptide of the invention.
    Type: Grant
    Filed: July 12, 2000
    Date of Patent: October 31, 2006
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: David D. Roberts, Henry C. Krutzsch